Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.70 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410907 | 1.00 | CHRNA7 (0.70) | CHRNA7HTR3AF10USP30MALT1 | |
| SCHEMBL6410342 | 1.00 | CHRNA7 (0.70) | CHRNA7HTR3AF10USP30MALT1 | |
| SCHEMBL6417861 | 0.87 | CHRNA7 (0.70) | CHRNA7HTR3AUSP30MLLT3MLLT1 | |
| SCHEMBL6413691 | 0.87 | CHRNA7 (0.70) | CHRNA7USP30MLLT3MLLT1SMYD3 | |
| SCHEMBL6414387 | 0.87 | CHRNA7 (0.70) | CHRNA7USP30MLLT3MLLT1SMYD3 | |
| SCHEMBL6417865 | 0.87 | CHRNA7 (0.70) | CHRNA7HTR3AUSP30MLLT3MLLT1 | |
| SCHEMBL6414385 | 0.87 | CHRNA7 (0.70) | CHRNA7USP30MLLT3MLLT1SMYD3 | |
| SCHEMBL6413684 | 0.87 | CHRNA7 (0.70) | CHRNA7HTR3AUSP30MLLT3MLLT1 | |
| SCHEMBL6415596 | 0.85 | CHRNA7 (0.56) | CHRNA7HTR3AUSP30 | |
| SCHEMBL6415603 | 0.85 | CHRNA7 (0.56) | CHRNA7HTR3AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | claimed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1476449-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003070732-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | CHRNA7 1475/4885HTR3A 2944/4885F10 2290/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | CHRNA7 1/4885HTR3A 788/4885F10 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.